(CercleFinance.com) – Crossject soars 10%, following the expansion of the geographic coverage of its December 2023 marketing agreement with an undisclosed partner for its emergency treatment of epileptic seizures, Zepizure.
Thanks to this extension, the contract now covers a total of 11 European countries. As a reminder, Crossject will receive milestone payments of up to one million euros, upon obtaining marketing authorizations in the relevant territories.
Crossject will sell Zepizure to its partner with a coefficient corresponding to a share of the gross margin. The company covers costs related to regulatory development and holds potential marketing authorizations.